TPP allies with Sprint Bioscience to develop cancer drugs

11/1/2012 | Pharmaceutical Business Review Online

Sprint Bioscience and TPP Global Development agreed to collaborate in the development of small molecule choline kinase inhibitors for treatment of cancer. "Choline kinase is an exciting metabolic target and fits well within the rest of TPP's cancer metabolism portfolio," TPP CEO Tom Brown said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA